Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | XDH | P47989 | 2/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990526 | 0.87 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3573863 | 0.87 | HSD17B2 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1808476 | 0.86 | TSHR (0.63) | CREBBPTSHRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL12650499 | 0.86 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31291728 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31291749 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28606187 | 0.84 | SMPD1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28794951 | 0.84 | NPC1 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1015707 | 0.83 | TSHR (0.73) | CREBBPTSHRMAPTSMN1; SMN2HPGD | |
| SCHEMBL6509038 | 0.83 | TAS1R3 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| CN-117693505-A | Heteroaryl derivative compounds and uses thereof | 沃若诺伊公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225238-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022225238-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2022-10-27 | — | — | WO | disclosed |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | CA12 3479/4885CA1 4508/4885CA2 3033/4885 |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA12 3049/4885CA1 1964/4885CA2 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.